These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37145121)

  • 61. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
    Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
    Lewis L; Sinha I; Losty PD
    Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.
    Makari D; Checchia PA; Devincenzo J
    Hum Vaccin Immunother; 2014; 10(3):607-14. PubMed ID: 24316863
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.
    Lacaze-Masmonteil T; Seidenberg J; Mitchell I; Cossey V; Cihar M; Csader M; Baarsma R; Valido M; Pollack PF; Groothuis JR;
    Drug Saf; 2003; 26(4):283-91. PubMed ID: 12608889
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland.
    Borecka R; Lauterbach R; Helwich E
    Dev Period Med; 2016; 20(3):181-190. PubMed ID: 27941187
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.
    Resch B
    Expert Rev Pharmacoecon Outcomes Res; 2008 Dec; 8(6):529-38. PubMed ID: 20528363
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P; Trenholme A; Abarca K; Griffin MP; Hultquist M; Harris B; Losonsky GA;
    BMC Pediatr; 2010 Jun; 10():38. PubMed ID: 20525274
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
    La Via WV; Notario GF; Yu XQ; Sharma S; Noertersheuser PA; Robbie GJ
    Pulm Pharmacol Ther; 2013 Dec; 26(6):666-71. PubMed ID: 23523663
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry.
    Cohen SA; Zanni R; Cohen A; Harrington M; VanVeldhuisen P; Boron ML;
    Pediatr Cardiol; 2008 Mar; 29(2):382-7. PubMed ID: 17926087
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A post-incorporation study on the use of palivizumab in the Brazilian public health system.
    Batista JDL; Ferreira MAP; Xavier CDS; Souza ITA; Cruz LN; Polanczyk CA
    Rev Inst Med Trop Sao Paulo; 2021; 63():e5. PubMed ID: 33533808
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

  • 76. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Respiratory virus prophylaxis in congenital heart disease.
    Joshi M; Tulloh RM
    Future Cardiol; 2018 Sep; 14(5):417-425. PubMed ID: 29877720
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
    Garegnani L; Styrmisdóttir L; Roson Rodriguez P; Escobar Liquitay CM; Esteban I; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013757. PubMed ID: 34783356
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis.
    Afghani B; Ngo T; Leu SY; Wu FL; Cecilio M; Aron-Johnson P; Zeitany R; Sills J; Amin A
    Pediatr Infect Dis J; 2006 Nov; 25(11):1019-24. PubMed ID: 17072124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.